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ABSTRACT 
Objectives 
There is previous epidemiological evidence that intake of polyphenol-rich foods has 
been associated with reduced cardiovascular disease risk. We aimed to investigate 
the effect of increasing dietary polyphenol intake on microvascular function in 
hypertensive participants. 
 
Methods  
All participants completed a 4-week run-in phase, consuming <2 portions of fruit and 
vegetables (F&V) daily and avoiding berries and dark chocolate.  Subjects were then 
randomized to continue with the low polyphenol diet for 8 weeks or to consume a 
high polyphenol diet of 6 portions fruit and vegetables (including 1 portion of 
berries/day and 50g of dark chocolate).  Endothelium-dependent (acetylcholine, 
ACh) and independent (sodium nitroprusside, SNP) vasodilator responses were 
assessed by venous occlusion plethysmography.  Compliance with the intervention 
was measured using food diaries and biochemical markers.   
 
Results 
Final analysis of the primary endpoint was conducted on 92 participants.  Between 
group comparison of change in maximum % response to ACh revealed a significant 
improvement in the high polyphenol group (p=0.02). There was a significantly larger 
increase in vitamin C, carotenoids and epicatechin in the high polyphenol group 
(between group difference p<0.001; p<0.001; p=0.008 respectively).  
 
Conclusions 
This study has shown that increasing the polyphenol content of the diet via 
consumption of fruit and vegetables, berries and dark chocolate results in a 
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significant improvement in an established marker of cardiovascular risk in 
hypertensive participants.  
KEY QUESTIONS 
 What is already known about this subject? 
Previous epidemiological and intervention study evidence suggests that increasing 
fruit and vegetable consumption improves cardiovascular disease risk.  More 
specifically, observational evidence to date indicates that polyphenol-rich foods, in 
particular berries and dark chocolate, may influence cardiovascular disease risk.  
However, there are few polyphenol-specific dietary intervention studies of sufficiently 
robust design that assess the effect of polyphenol-rich foods on microvascular 
function.  
 
 What does this study add? 
 Our group conducted a randomised control trial and found that increasing 
intake of polyphenol-rich foods, in the form of fruit and vegetables (including berries) 
and dark chocolate, for 8 weeks resulted in a significant improvement in 
endothelium-dependent vasodilation in hypertensive participants.  
  
How might this impact on clinical practice? 
This study suggests that a well-tolerated polyphenol-rich diet through the simple 
addition of berries and dark chocolate could have a positive effect on microvascular 
function and cardiovascular risk. 
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Previous epidemiological and intervention study evidence suggests that increasing 
fruit and vegetable (F&V) consumption improves cardiovascular disease (CVD) risk  (1). A previous dietary intervention by McCall and colleagues in hypertensive 
subjects (Fruit and Vegetable Randomised Intervention Trial, FAVRIT) demonstrated 
a 6% improvement in endothelium-dependent vasodilation, as a measure of vascular 
function, for every portion/day increase in fruit or vegetables  (2).  Post-hoc analysis 
of the FAVRIT data indicated that berry consumption was the class of fruit most 
associated with an improvement in microvascular function.  It was hypothesised that 
this could be attributed to berries high polyphenol content. Observational evidence to 
date indicates that polyphenol-rich foods, in particular berries  (3,4) and dark 
chocolate  (5-7), may influence CVD risk.  However, there are few polyphenol-
specific dietary intervention studies of sufficiently robust design that assess the effect 
of polyphenol-rich foods on microvascular function.  
 
The aim of the Polyphenol Intervention Trial (PPhIT) was to investigate if increasing 
overall polyphenol dietary intake (through the consumption of six portions of F&V/day 
including one portion of berries, and 50g of dark chocolate) would affect 
microvascular function, measured by forearm blood flow (FBF) responses to an 
endothelium-dependent vasodilator, and also have a beneficial effect on a range of 
other markers of CVD risk, such as systolic blood pressure and lipid profile, in 
patients with hypertension. 
 
The FBF measure of microvascular function was chosen as the primary endpoint, not 
only due to its use in previous dietary interventions, including the FAVRIT study (2), 
but also because responses to endothelium- dependent vasodilators such as 
acetylcholine (ACh) have previously been shown to be reduced in individuals with 
hypertension  (8,9).  FBF responses to ACh have also been independently 
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associated with cardiovascular morbidity in hypertensive patients  (10) and, in those 
with established CVD, improved FBF responses were significantly correlated with 
improved survival after acute coronary syndrome  (11).  
 
Participants with hypertension were chosen because they represent a common 
cardiovascular risk cohort in whom modification of diet is feasible.   There are several 
studies linking hypertension with reduced response to endothelium- dependent 
vasodilators  (8,9,12). In addition, the current ESC guidelines for management of 
hypertension endorse increasing F&V intake to five portions per day, based on 
studies of a Mediterranean diet  (13), making it a relevant population in which to 
conduct a randomised controlled dietary intervention trial  (14).  
 
METHODS 
Overview of study and endpoints 
The study used a twelve-week randomized controlled, single-blinded dietary 
intervention design. The study commenced with a four-week ‘run-in phase’ for all 
participants, during which they were asked to consume two portions or less of F&V, 
and to exclude berries and dark chocolate (low polyphenol diet).  At the end of this 
period, subjects were randomized to continue with the above low polyphenol diet for 
a further eight week ‘intervention period’ or to consume a high polyphenol diet of six 
portions F&V (including one portion of berries per day) and 50g of dark chocolate per 
day (Figure 1).   
 
The primary endpoint was between group change in maximum FBF response to the 
endothelium-dependent vasodilator, ACh.  Secondary endpoints included between 
group change in self-reported polyphenol-rich food intake, between group change in 
biochemical markers of nutritional status, and between group change in systolic 
blood pressure and lipid profile.  The study had ethical approval from the Office of 
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Research Ethics Committee Northern Ireland (ref 10/NIR03/39) and was registered at 
ClinicalTrials.gov (ref NCT01319786). 
 
Inclusion Criteria 
Participants aged 40-65 years, with documented grade I (140-159/90-99mmHg) or 
grade II (160-179/100-109mmHg) hypertension, were eligible (15).  Potential 
participants had brachial blood pressure (BP) measured after ten minutes rest using 
an Omron M5-1 automatic BP monitor (Omron Healthcare, Hoofdorp, Netherlands) 
from the dominant arm.  Three consecutive measurements were recorded and a 
summary BP calculated from the 2nd and 3rd readings.   
 
Exclusion Criteria 
Exclusion criteria included diabetes mellitus, acute coronary syndrome or transient 
ischaemic attack within three months, pregnancy or lactation, fasting triglyceride 
concentration >4mmol/l, alcohol consumption (>28 units/week for men and >21 
units/week for women), oral anticoagulant therapy or antioxidant supplements, 
dietary restrictions that would limit ability to comply with the study diets and body 
mass index >35kg/m2 with an impalpable brachial artery.  
 
Randomisation 
Participants’ baseline habitual polyphenol dietary content was measured at the 
screening visit using a modified version of the food frequency questionnaire 
developed for the European Prospective Investigation of Cancer study  (16). Eligible 
participants were stratified into high or low polyphenol consumers and then block 
randomized using a random-number generator (www.randomization.com, block size 
n=6).  The investigator performing FBF assessment (RN) and staff conducting 
laboratory analysis were blinded to diet allocation.  
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Dietary intervention  
Participants received individual nutrition consultations with a nutrition researcher 
(CR), as well as literature regarding portion sizes based on the United Kingdom Food 
Standard Agency guidelines (www.eatwell.gov.uk). All participants in the high 
polyphenol diet had a self-selected weekly delivery of F&V and dark chocolate 
(Lindt 70% cocoa) free of charge to their homes from a local supermarket. Each 
participant was also contacted by telephone at weekly intervals.  At each study visit, 
weight, hip and waist circumference were measured and questionnaires completed 
to quantify any change in level of physical activity. 
 
Measurement of compliance 
Dietary compliance was assessed using four-day food diaries on four occasions, two 
unannounced 24-hour recalls and daily study food records completed by participants.  
Biochemical assessment of nutritional status included measurement of plasma 
vitamin C and carotenoids.  To specifically monitor for dark chocolate consumption, 
urinary epicatechins were measured, as these represent one of the major 
polyphenols in cocoa  (17).  
 
Assessment of vascular function 
Participants attended for assessments of microvascular function pre- and post- the 
eight-week intervention period. Room temperature was maintained at 22-24°C.  All 
testing was performed by a single investigator (RN) who remained blinded to 
intervention phase dietary allocations throughout the study and during statistical 
analysis.  Participants attended between 7am-11am, having fasted for at least 12 
hours and refrained from ingestion of caffeine, alcohol, nicotine or long-acting nitrate 
preparations. 
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Venous occlusion plethysmography was used to determine FBF during intra-arterial 
infusions of ACh and SNP, endothelium-dependent and -independent vasodilators, 
respectively.  Each FBF study was conducted according to an established standard 
operating procedure within the facility  (2).  After infiltration with 1% lidocaine, a 27-
gauge sterile needle (Cooper’s Needle Works, Birmingham, UK) was inserted into 
the non-dominant brachial artery using an aseptic technique. At baseline and during 
vasodilator administration, plethysmographic measurements were made with 
electrically calibrated mercury-in-Silastic strain gauges (PMS Instruments, 
Maidenhead, UK) in both the infused and noninfused limbs, to control for unexpected 
stimuli  (18). Each strain gauge was attached to a Hokanson EC6 plethysmograph 
(PMS Instruments), which in turn was connected to a dedicated computer on which 
the Hokanson NIVP3 Dual Channel software (Version 5.40, PMS Instruments) was 
installed. Initially saline was infused through the needle via an epidural catheter at a 
rate of 1 mL/min for at least 30 minutes, followed by incremental intra-arterial 
infusions of acetylcholine (50, 100, and 200 nmol/min) and sodium nitroprusside (5, 
10, and 20 nmol/min).  Each concentration was infused for 5 minutes before five 
forearm blood flow readings were made during 7-second periods of venous occlusion 
separated by 20-second intervals. 
 
Mean inflow curve gradients for each concentration of both infusions were calculated 
using NIVP3 software.  This was performed for infused and control arms to yield flow 
rates in ml/100ml forearm volume (i.e. % change). Each participant’s responses were 
summarised by curves of % increase in infused:non-infused ratio against vasodilator 
dose.  The summary measure used was maximum vasodilator response observed  
(10).  
 
Laboratory analysis 
Plasma vitamin C was measured on a FLUOstar Optima plate reader (BMG Labtech, 
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Ortenberg, Germany) adapted from the method by Vuilleumier & Keck  (19). Serum 
concentrations of six carotenoids (α-carotene, β-carotene, β-cryptoxanthin, lutein, 
lycopene, and zeaxanthin) were measured by reverse phase high performance liquid 
chromatography (HPLC) as described by Craft  (20). Fasting serum lipid profiles 
(total cholesterol, high density lipoprotein (HDL) and triglycerides) were assessed 
using standard enzymatic colorimetric assays on an automated Cobas® 8000 
Modular system biochemical analyser (Roche Diagnostics Ltd, West Sussex, UK). 
Low-density lipoprotein (LDL) cholesterol was calculated using a standard 
Friedewald formula  (21).  Urine collected from the volunteers between evening meal 
and midnight the evening before each study visit was analysed, including an 
enzymatic hydrolysis step, to quantify total epicatechin content using an Agilent 
Technologies 1100 series HPLC (Agilent Technologies, Stockport, UK) directly linked 
to a Waters Micromass Quattro Ultima Platinum API triple quadrupole mass 
spectrometer (Waters, Dublin, Ireland).   
 
Statistical analysis and power calculation 
Results are expressed as mean ± standard deviation for normally distributed 
continuous variables. Skewed variables were log- transformed and summarized as 
geometric mean and interquartile range (IQR), where appropriate. The principal 
analysis for each outcome variable was a between group comparison of change 
using independent sample t tests or chi squared test.  These analyses were 
confirmed using analysis of covariance (ANCOVA) using post intervention values as 
the outcome variable and adjusting for pre intervention values.  Within group 
comparisons were performed using paired samples t tests.  Univariate linear 
regression analysis was also used to further examine vascular function results. All 
statistical analyses were performed using SPSS version 20 (SPSS. Inc, Chicago, IL).   
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The power calculation was based on data collected as part of the FAVRIT study  (2). 
To detect a 33% difference (the difference detected in FAVRIT) between groups in 
this variable with 90% power using a 2-tailed test at the 5% significance level would 
require 50 participants per group.  Participants who were found to have an elevated 
highly sensitive C-reactive protein (hsCRP) >10mg/l at any point in the study, 
indicating acute inflammation, were excluded from final analysis, in line with 
American Heart Association guidelines  (22). 
 
RESULTS 
Summary of recruitment 
The CONSORT recruitment summary is illustrated in Figure 2. Overall, 155 
individuals attended for screening.  Of these, 51 (33%) did not meet the inclusion 
criteria or were unable to participate.  In total, 104 participants commenced the study; 
two withdrew during the wash out period due to family or work reasons.  At 
randomization, 102 patients (51 per group) were allocated to either a high or low 
polyphenol diet.  There were three dropouts during the intervention phase: two from 
the high polyphenol group due to personal reasons and a change in antihypertensive 
therapy respectively, and one from the low polyphenol group due to personal illness.  
Therefore, 99 participants completed the study between January 2010 and April 
2013.  
 
Of these, six had a recorded serum hsCRP>10mg/l at one or more time points during 
the study and were excluded from further analyses.  Of the remaining 93 participants, 
there were missing post-intervention plasma samples required for vitamin C analysis 
for one participant, one patient did not return a complete set of food diaries, and 
post-intervention FBF studies had to be abandoned in another patient due to 
computer hardware issues on that visit.  A full data set was therefore available on a 
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total of 90 participants.  Baseline results prior to entry to washout period are not 
shown. 
 
Baseline characteristics 
Baseline pre-intervention characteristics recorded after the 4-week run-in period are 
summarized in Table 1.  There were no significant differences between the two 
groups, with the exception of total cholesterol and low-density lipoprotein (LDL), 
which were both higher in the high polyphenol group (p=0.020 and p=0.038 
respectively).   
 
Changes in measure of compliance 
Results for self-reported polyphenol intake and micronutrients are summarized in 
Table 2. Between group change showed a significant increase in self-reported 
polyphenol intake in the high polyphenol group compared with the low polyphenol 
group (p<0.001 for all).  There was also a significant between-group difference in 
change in micronutrient status: concentrations of urinary epicatechin (p<0.001), 
plasma vitamin C (p<0.001) and all serum carotenoids (with the exception of 
lycopene (p=0.098)) with a significantly larger increase in the high polyphenol group 
compared to the low polyphenol group.  
 
Changes in microvascular function 
Comparison between the two dietary groups showed maximum % response to ACh 
(infused:non-infused arm ratios) was significantly improved in the high polyphenol 
group (p=0.02) relative to the control group (Table 3). There was no significant 
difference in the between group change in response to SNP (p=0.17).  Dose 
response curves were plotted for mean saline and infused:non-infused ratios for 
each ACh concentration per group pre- and post-intervention (Figure 3) to illustrate 
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the improvement in high polyphenol FBF post-intervention.  Further analysis of 
microvascular function is included in Appendix 1. 
 
Changes in markers of cardiovascular risk 
There were no significant changes in BMI within (low polyphenol group 29.8 kg/m2 
pre- and 29.8 kg/m2 –post (p=0.842), high polyphenol group 31.6 kg/m2 and 31.6 
kg/m2 –post (p=0.961)) or between groups (p=0.897) during the intervention (Table 
3). There was a trend towards a larger decrease in systolic blood pressure (SBP) in 
the high polyphenol group compared to the low polyphenol group; this was of 
borderline statistical significance (p=0.059).  Within-group analysis found that SBP 
decreased significantly within both the low polyphenol (141.7±9.3 mmHg pre- vs 
136.9±10.6 mmHg post-, p<0.001) and high polyphenol group (140.6±8.9 mmHg pre- 
vs 131.6±12.5 mmHg post-, p=0.001) by 4.8mmHg and 9.0mmHg respectively.   
There was a significant between-group difference in change in total cholesterol with 
the high polyphenol diet showing an improvement (0.2 mmol/L reduction) compared 
with an increase in concentration in the low polyphenol diet (0.1 mmol/L increase) 
p=0.042).  There were no significant between-group differences in change in any of 
the remaining lipid parameters.  
 
DISCUSSION 
The PPhIT study aimed to extend a previous dietary intervention (FAVRIT) that had 
been shown to improve microvascular function in hypertensive subjects. This study 
develops those findings by showing that increasing polyphenol content with the 
addition of berries and dark chocolate potentially has additional benefits on 
microvascular function and CVD risk. The ideal combination of polyphenol-rich foods 
for cardiovascular health remains under debate. It was hypothesized that this diet 
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would provide increased benefits to cardiovascular health and, importantly, given its 
palatability, be easily adopted by the general public.  
 
The primary endpoint of the PPhIT study was between group change in maximum 
FBF response to the endothelium-dependent vasodilator, ACh.  Between group 
comparison showed that those subjects who received a high polyphenol diet had a 
significantly greater improvement in maximum % response to ACh, compared to the 
low polyphenol group (p=0.02). This suggests that increasing consumption of 
polyphenol-rich foods improves endothelium-dependent forearm blood flow response 
in hypertensive volunteers.   
 
Therefore, the present findings indicate that increasing polyphenol intake, and 
specifically including berries, alongside consumption of a moderate portion of dark 
chocolate, could result in a significant improvement in endothelium-dependent 
responses. The available prognostic association data (10) suggest that improving 
endothelium-dependent FBF with a diet rich in polyphenols could potentially modify 
CVD risk.  An effect due to displacement of other foods from participants’ diets 
cannot, however, be excluded. 
There was a significant between group change in reported fruit and vegetable intake. 
Given that self-reported data is prone to reporting bias, independent confirmation 
was provided by biomarkers, including assessment of plasma vitamin C and a panel 
of serum carotenoids.  This indicated good compliance with the dietary intervention. 
The epicatechin content of the dark chocolate provided to participants was not 
measured during this study.  However, previous studies have measured epicatechin 
levels in the brand of dark chocolate used in this intervention. Using this data, the 
amount of dark chocolate provided would have delivered a dose of 35.7mg 
epicatechin/day (23). Compliance with dark chocolate was demonstrated by a 
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significant increase in evening meal to midnight urinary epicatechin levels detected 
on between group testing. Urinary epicatechin use has been found to be superior to 
plasma epicatechin measurement as peak levels are detected 6-12h post-
consumption  (24,25).  The addition of dark chocolate to the regimen may have 
increased the palatability of the diet. Participant feedback showed a 90% approval 
rating for the overall diet, indicating that it was well tolerated  (26).  
 
There was a trend towards greater lowering in SBP within the high polyphenol group 
compared to the low polyphenol group (mean change: -9.1±12.4mmHg vs -
4.8±8.7mmHg respectively, p=0.059) on between group analysis. Both SBP and DBP 
decreased significantly on within group analysis.  However, the decrease in blood 
pressure in both active and control groups may represent ‘regression to the mean’  
(27), a phenomenon has been described in previous BP studies  (2). Few polyphenol 
dietary intervention trials have assessed SBP. Previous calculations estimate that 
115 participants would be required per group to detect a 5mmHg change in SBP with 
90% power; therefore this study may have been underpowered to detect a difference 
in SBP between groups, and a type II error is possible  (2).   
 
Between group testing demonstrated a significantly greater reduction in total 
cholesterol (p=0.042) and a trend for greater decrease in LDL (p=0.063) in the high 
polyphenol group compared to the low polyphenol group.  To put this into a clinical 
context, the change post-intervention in LDL in high polyphenol group in the PPhIT 
study equated to a 4.3% decrease in LDL concentrations, which, based on published 
data, would equate to a reduction in CVD mortality of approximately 4% (28). 
 
In contrast to the PPhIT study, most polyphenol studies have used single food 
interventions. Combining different polyphenol-rich foods may provide a cumulative 
increase in benefit due to the synergistic effect of several bioactive compounds. 
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Potential mechanisms for the beneficial effects of polyphenols include: their 
antioxidant and vasodilator functions, their ability to alter the expression of 
endothelial nitric oxide synthase, and their ability to induce production of other 
endogenous vasodilators.  However, many other cardiovascular benefits may exist, 
as described in recent reviews (29,30).  The participants in the PPhIT study were 
free-living and allowed to make their own choices of type of F&V to be consumed.  
They also had hypertension, and other cardiovascular risk factors.  The results 
therefore are more relevant to ‘real-life’ than studies involving in-patient admission or 
supervised meals.   
 
A concerted effort was made to keep other lifestyle variables constant during the 
study, reflected by static BMI and activity levels.  However, in free-living individuals it 
is impossible to control for all variables in lifestyle.  Due to budget and time 
constraints the PPhIT study was unable to use a factorial design to allow 
examination of the specific effect of berries and dark chocolate over and above 
increasing fruit and vegetable intake alone.  As such this study cannot conclusively 
state whether polyphenols or other bioactive components within these foods, such as 
carotenoids or vitamin C, working in isolation or synergistically, have led to the 
improvement in the primary endpoint.  Future work could include comparison 
between low and high fruit and vegetable versus high polyphenol diets to definitively 
test the hypothesis that a greater improvement in FBF responses to ACh can be 
achieved with specific inclusion of polyphenol-rich foods, compared to a fruit and 
vegetable-rich diet alone.  
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CONCLUSIONS 
Increasing intake of polyphenol-rich foods, in the form of fruit and vegetables, berries 
and dark chocolate, for 8 weeks resulted in a significant improvement in 
endothelium-dependent vasodilation in hypertensive participants. This study 
suggests that a well-tolerated polyphenol-rich diet could have a positive effect on 
microvascular function and cardiovascular risk.  
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TABLES 
Table 1- Pre-eight week intervention period participant characteristics according to 
diet allocation. 
 Low 
polyphenol 
(n=47) 
High 
polyphenol 
(n=46) 
Between group 
comparison P-
value 
Age(years)* 55.6 (6.8) 54.0 (6.7) 0.235 
Males(%)§ 28 (59.6) 22 (47.8) 0.301 
Body Mass Index(kg/m2)* 29.8 (5.0) 31.6 (6.5) 0.148 
Systolic blood 
pressure(mmHg)* 
141.7 (9.3) 140.6 (8.9) 0.589 
Diastolic blood 
pressure(mmHg)* 
85.5 (6.9) 84.5 (7.6) 0.460 
Current smoker(%)§ 4 (8.5) 6 (13.0) 0.523 
Former smoker(%)§ 24 (51.1) 18 (39.1) 0.300 
Anti-hypertensive therapy(%)§ 37 (78.7) 36 (78.3) 0.999 
Lipid-lowering therapy(%)§ 21 (44.7) 19 (41.3) 0.835 
Total cholesterol(mmol/L)* 5.2 (1.2) 5.8 (1.3) 0.020 
HDL(mmol/L)* 1.4 (0.4) 1.4 (0.4) 0.568 
LDL(mmol/L)* 4.2 (1.3) 4.7 (1.4) 0.038 
Triglycerides(mmol/L)† 1.6 (1.0,2.3) 1.6 (1.1,2.1) 0.796 
Total cholesterol/HDL ratio* 3.9 (1.3) 4.2 (1.2) 0.267 
Max response ACh 
(infused:noninfused)(%)*‡ 
123.9 (99.6) 
 
109.1 (84.7) 0.447 
Max response SNP 
(infused:noninfused)(%)*‡ 
126.3(120.4) 107.7(70.1) 0.369 
  18 
HDL- high-density lipoprotein; LDL- low-density lipoprotein; ACh- acetylcholine; SNP- sodium 
nitroprusside.  
*Normally distributed data summarized as mean (SD).  Difference between groups assessed 
using independent samples t-test.  
†Skewed data was logarithmically transformed and presented as geometric mean (IQ range). 
Difference between groups assessed using independent samples t-test. 
§Categorical variables are summarized as n (%).  Difference between groups assessed using 
Chi-square test.  
‡based on 92 subjects due to missing data for one participant in low polyphenol group. 
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Table 2- Pre- and post-intervention period results of self reported dietary intake and micronutrient concentrations by diet allocation 
 Low polyphenol 
(n=47) 
Change Within 
group P-
value 
High polyphenol 
(n=46) 
Change Within 
group P-
value 
Between 
group P-
value Pre Post Pre Post 
F&V intake*‡ 
(portions/day) 
1.38(0.80) 1.25(0.57) -0.13  
(-0.35,0.10) 
0.252 1.40 (0.71) 6.82 (2.12) 5.42  
(4.71,6.14) 
<0.001 <0.001 
Berries 
(portions/day)§‡ 
0 0 0 N/A 0 1.00 
(0.80,1.25) 
1.00 
(0.77,1.25) 
<0.001 <0.001 
Dark 
Chocolate 
(g/day)§‡ 
0 0 0 N/A 0 
 
50.0  
(37.5,50.0) 
50.0 
(37.5,50.0) 
<0.001 <0.001 
Epicatechin 
(nmol/mol crt)* 
0.12(0.20) 0.10 (0.12) -0.02 
(-0.08,0.06) 
0.629 0.10(0.30) 0.30(0.29) 0.19 
(0.07,0.31) 
0.002 <0.001 
Vitamin C 
(µmol/l)†‡ 
 
25.1  
(18.3,52.3) 
19.6 
(11.8,48.9) 
0.79  
(0.63, 0.96)  
0.021 28.4  
(18.6,57.5) 
51.7 
(43.9,68.6) 
1.82  
(1.34, 7.25)  
<0.001 <0.001 
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 Low polyphenol 
(n=47) 
Change Within 
group P-
value 
High polyphenol 
(n=46) 
Change Within 
group P-
value 
Between 
group P-
value 
 Pre Post   Pre Post    
Lutein(µmol/l)† 0.16 
(0.12,0.20) 
0.15 
(0.11,0.20) 
0.98  
(0.90, 1.06)  
0.595 0.15 
(0.11,0.19) 
0.20 
(0.15,0.26) 
1.32  
(1.22, 1.44)  
<0.001 <0.001 
Zeaxanthin 
(µmol/l)† 
0.04 
(0.03,0.05) 
0.04 
(0.03,0.05) 
0.97  
(0.91, 1.03)  
0.331 0.04 
(0.03,0.05) 
0.05 
(0.04,0.06) 
1.18  
(1.07, 1.30)  
0.001 0.001 
βcryptoxanthin 
(µmol/l)† 
0.05 
(0.04,0.08) 
0.05 
(0.03,0.08) 
0.92  
(0.83, 1.03)  
0.134 0.05 
(0.04,0.07) 
0.07 
(0.05,0.10) 
1.29  
(1.15, 1.45)  
<0.001 <0.001 
α-carotene 
(µmol/l)† 
0.12 
(0.09,0.16) 
0.11 
(0.08,0.14) 
0.90 
(0.82, 0.99) 
0.037 0.12 
(0.10,0.15) 
0.14 
(0.11,0.20) 
1.17  
(1.05, 1.30)  
0.006 0.001 
β-carotene 
(µmol/l)† 
 
0.24 
(0.15,0.36) 
0.21 
(0.14,0.32) 
0.91  
(0.82, 1.01)  
0.064 0.26 
(0.19,0.36) 
0.30 
(0.23,0.42) 
1.16 
(1.05, 1.28)  
0.006 0.001 
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F&V- fruit and vegetables, N/A- not applicable 
•Normally distributed variables at baseline were summarised as mean (SD). Within group change assessed using paired samples t test and between group 
differences in change assessed using independent samples t test. Change expressed as mean difference (95%CI).   
†Skewed variables were logarithmically transformed and baseline values summarised as geometric mean (IQR).  Within group change assessed using paired 
samples t test and between group differences in change assessed using independent samples t-test. Change expressed as geometric mean (95%CI), which, 
due to the logarithmic transformation, represents the ratio of the post to pre value.  
§Non-parametric data at baseline presented as median (IQR).  Within group change assessed using Wilcoxon Signed Rank test and between group 
differences In change calculated using Mann-Whitney U-test.  Change expressed as median difference (IQR). 
 Low polyphenol 
(n=47) 
Change Within 
group P-
value 
High polyphenol 
(n=46) 
Change Within 
group P-
value 
Between 
group P-
value 
 Pre Post   Pre Post    
Lycopene 
(µmol/l)† 
0.45 
(0.33,0.69) 
0.43 
(0.33,0.58) 
0.95  
(0.85, 1.06)  
0.343 0.47 
(0.38,0.66) 
0.53 
(0.41,0.69) 
1.12  
0.95, 1.31)  
0.177 0.098 
Total 
carotenoids 
(µmol/l)† 
1.09 
(0.84,1.47) 
0.99 
(0.75,1.34) 
0.93  
(0.86, 1.09)  
0.800 1.13 
(0.91,1.36) 
1.32 
(1.06,1.67) 
1.17  
(1.06, 1.29)  
0.003 0.001 
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‡Based on 92 patients due to incomplete food diary and insufficient Vitamin C sample in high polyphenol group.  
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Table 3 Pre- and post-intervention period results of cardiovascular risk assessments by diet allocation 
 Low polyphenol 
(n=47) 
Change Within 
group P-
value 
High polyphenol 
(n=46) 
Change Within 
group P-
value 
Between 
group P-
value Pre Post Pre Post 
Max response to 
Ach, infused:non-
infused(%)*‡ 
123.9  
(99.6) 
 
136.7 
(143.7) 
12.8  
(-34.8,60.4) 
0.590 109.1 
(84.7) 
225.0 
(180.4) 
115.9  
(70.1, 161.6) 
<0.001 0.02 
Max response to 
SNP, infused:non-
infused(%)*‡ 
126.3 
(120.4) 
106.5  
(87.7) 
-19.7  
(-59.9,18.4) 
0.303 107.7 
(70.1) 
120.2 
(92.5) 
12.5  
(-14.7, 39.7) 
0.358 0.169 
Systolic blood 
pressure(mmHg)* 
141.7  
(9.3) 
136.9  
(10.6) 
-4.83  
(-7.38,-2.28) 
<0.001 140.6 
(8.9) 
131.6 
(12.5) 
-9.06  
(-12.8,-5.40) 
<0.001 0.059 
Diastolic blood 
pressure(mmHg)* 
 
 
85.5  
(6.9) 
82.0  
(6.1) 
-3.53  
(-5.24,-1.82) 
<0.001 84.5 
(7.6) 
79.1 
(8.2) 
-5.35  
(-7.81,-2.88) 
<0.001 0.227 
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 Low polyphenol 
(n=47) 
Change Within 
group P-
value 
High polyphenol 
(n=46) 
Change Within 
group P-
value 
Between 
group P-
value 
 Pre Post   Pre Post    
Body mass 
index(kg/m2)* 
29.8(5.0) 29.8(5.0) 0.01  
(-0.10,0.12) 
0.842 31.6(6.3) 31.6 
(6.5) 
-0.01  
(-0.24,0.23) 
0.961 0.897 
Total 
cholesterol(mmol/
L)* 
5.2(1.2) 5.3(1.1) 0.10 
(-0.08,0.28) 
0.250 5.8(1.3) 5.6(1.0) -0.21 
-0.57,0.04) 
0.097 0.042 
HDL(mmol/L)* 1.4(0.4) 1.4(0.3) 0.01 
(-0.03,0.05) 
0.725 1.4(0.4) 1.5(0.4) 0.02 
(-0.03,0.06) 
0.482 0.753 
LDL(mmol/L)* 4.2(1.3) 4.3(1.2) 0.08 
(-0.10,0.26) 
0.366 4.7(1.4) 4.5(1.0) -0.25 
(-0.57,0.06) 
0.109 0.063 
Triglycerides 
(mmol/L) † 
1.6 
(1.0, 2.32) 
1.5 
(1.1, 2.4) 
0.97  
(0.90, 1.05)  
0.470 1.6 
(1.1, 2.1) 
1.6 
(1.1, 2.3) 
0.99  
(0.89, 1.10)  
0.825 0.807 
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ACh= acetylcholine, SNP= sodium nitroprusside, 95%CI= 95% confidence intervals, HDL- high-density lipoprotein; LDL- low-density lipoprotein 
•Normally distributed variables at baseline were summarised as mean (SD). Within group change assessed using paired samples t test and between group 
differences in change assessed using independent samples t test. Change expressed as mean difference (95%CI).   
†Skewed variables were logarithmically transformed and baseline values summarised as geometric mean (IQR).  Within group change assessed using paired 
samples t test and between group differences in change assessed using independent samples t-test. Change expressed as geometric mean (95%CI), which, 
due to the logarithmic transformation, represents the ratio of the post to pre value.  
‡Based on 92 subjects due to missing microvascular function data on one patient in low polyphenol group. 
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ABBREVIATIONS 
ACh- acetylcholine 
BMI- body mass index 
BP- blood pressure 
CVD- cardiovascular disease 
F&V- fruit and vegetables 
FAVRIT- fruit and vegetable randomised intervention trial 
FBF- forearm blood flow 
hsCRP- highly sensitive C-reactive protein 
IQR- interquartile range 
LDL- low density lipoprotein 
PPhIT- polyphenol intervention trial 
SBP- systolic blood pressure 
SD- standard deviation 
SNP- sodium nitroprusside 
 
 
  28 
REFERENCES 
 1. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt 
TM, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on 
blood pressure.  DASH Collaborative Research Group. The New England Journal of Medicine 
1997;336:1117-1124. 
2. McCall DO, McGartland CP, McKinley MC, Patterson CC, Sharpe P, McCance DR, Young 
IS, Woodside JV. Dietary intake of fruits and vegetables improves microvascular function in 
hypertensive subjects in a dose-dependent manner. Circulation 2009;119:2153-2160. 
3. Cassidy A, Mukamal KJ, Liu L, Franz M, Eliassen AH, Rimm EB. High anthocyanin intake 
is associated with a reduced risk of myocardial infarction in young and middle-aged women. 
Circulation 2013;127:188-196. 
4. McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT. Flavonoid intake 
and cardiovascular disease mortality in a prospective cohort of US adults. The American 
Journal of Clinical Nutrition 2012;95:454-464. 
5. Buijsse B, Feskens EJM, Koh FJ, Kromhout D. Cocoa intake, blood pressure and 
cardiovascular mortality.  The Zutphen Elderly Study. Archives of Internal Medicine 
2006;166:411-417. 
6. Buijsse B, Weikert C, Drogan D, Bergmann M, Boeing H. Chocolate consumption in 
relation to blood pressure and risk of cardiovascular disease in German adults. European 
Heart Journal 2010;31:1616-1623. 
7. Jansky I, Mukamal KJ, Ljung R, Ahnve S, Ahlbom A, Hallqvist J. Chocolate consumption 
and mortality following a first acute myocardial infarction: the Stockholm Heart Epidemiology 
Program. Journal of Internal Medicine 2009;266:248-257. 
8. Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelium-dependent 
vascular relaxation in patients with essential hypertension. The New England Journal of 
Medicine 1990;323:22-27. 
9. Linder L, Kiowski W, Buhler FR, Lushcer TF. Indirect evidence for release of endothelium-
derived relaxing factor in human forearm circulation in vivo. Circulation 1990;81:1762-1767. 
10. Perticone F, Ceravolo R, Puja A, Ventura G, Iacopina S, Scozzafava A, Ferraro A, Chello 
M, Mastroroberto P, Verdecchia P, Schillaci G. Prognostic significance of endothelial 
dysfunction in hypertensive patients. Circulation 2001;104:191-196. 
11. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial 
dysfunction in patients with acute coronary syndromes: further evidence for the existence of 
the "vulnerable" patient. Circulation 2004;110:1926-1932. 
12. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, Sudano I, Salvetti A. 
Aging and endothelial function in normotensive subjects and patients with essential 
hypertension. Circulation 1995;91:1981-1987. 
13. ESH/ESC. 2013 ESH/ESC guidelines for the management of arterial hypertension. The 
Task Force for the managment of arterial hypertension of the European Society of 
Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013; 
14. Eckel RH, Jakicic JM, Ard JA, de Jesus JM, Miller NH, Hubbard VS, Lee I, Lichenstein 
AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith Jr SC, Svetkey LP, Wadden TA, 
  29 
Yanovski SZ. 2013 AHA/ACC Guideline on lifestyle management to reduce cardiovascular 
risk. Circulation 2014;129:S76-S99. 
15. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG 
Thom S. British Hypertension Society guidelines for hypertension management (BHS-IV): 
summary. British Medical Journal 2004;328:634-640. 
16. Kroke A, Klipstein-Grobusch K, Voss S, Möseneder J, Thielecke F, Noack R, Boeing H. 
Validation of a self-administered food-frequency questionnaire administered in the European 
Prospective Investigation into Cancer and Nutrition (EPIC) Study: comparison of energy, 
protein, and macronutrient intakes estimated with the doubly labeled water, urinary nitrogen, 
and repeated 24-h dietary recall methods. The American Journal of Clinical Nutrition 
1999;70:439-447. 
17. Spencer JPE, Mohsen MMAE, Minihane A, Mathers JC. Biomarkers of the intake of 
dietary polyphenols: strengths, limitations and application in nutrition research. British Journal 
of Nutrition 2008;99:12-22. 
18. Wilkinson IB, Webb DJ. Venous occlusion plethysmography in cardiovascular research: 
methodology and clinical applications. British Journal of Clinical Pharmacology 2001;38:1461-
1466. 
19. Vuilleumier JP, Keck E. Fluorometric assay of vitamin C in biological materials using a 
centrifugal analyser with fluorescence attachment. Journal of Micronutrient Analysis 
1989;5:25-34. 
20. Craft NE. Carotenoid reversed-phase hihg-performance liquid chromatography methods: 
reference compendium. Methods in Enzymology 1992;213:185-205. 
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density 
cholesterol in plasma without use of the preparitive ultracentrifuge. Clinical Chemistry 
1972;18:499-502. 
22. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M, Fadl 
YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith Jr JC, Taubert K, Tracy RP, Vinicor F. 
Markers of inflammation and cardiovascular disease: application to clinical and public health 
practice: a statement for healthcare professionals from the Centers for Disease Control and 
Prevention and the American Heart Association. Circulation 2003;107:499-511. 
23. Gottumukkala RVSS, Nadimpalli N, Sukala K, Subbaraju GV. Determination of catechin 
and epicatechin content in chocolates by high-performance liquid chromatography. 
International Scholarly Research Notes 2014;2014:1-5. 
24. Roura E, Almajano MP, Bilbao MLM, Andrés-Lacueva C, Estruch R, Lamuela-Raventós 
RM. Human urine: epicatechin metabolites and antioxidant activity after cocoa beverage 
intake. Free Radical Research 2007;41:943-949. 
25. Baba S, Osakabe N, Kato. Y., Natsume M, Yasuda A, Kido T, Fukada K, Muto Y, Kondo 
K. Continuous intake of polyphenolic compounds containing cocoa powder reduces LDL 
oxidative susceptibility and has beneficial effects on plasma HDL-cholesterol concentrations 
in humans. American Journal of Clinical Nutrition 2007;85:709-717. 
26. Rooney C. Polyphenol intake, Dietary Patterns and Psychological Analysis . 2013; 
27. Tu Y, Gilthorpe MA. Revisiting the relation between change and initial value: a review and 
evaluation. Statistics in Medicine 2007;26:443-457. 
  30 
28. Grundy SM, Cleeman JI, Merz NB, Brewer Jr HB, Clark LT, Hunninghake DB, Pasternak 
RC, Smith Jr SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol 
Education Program Adult Treatment Panel II Guidelines. Journal of the American College of 
Cardiology 2004;44:720-732. 
29. Nijveldt RJ, Van Nood E, Van Hoorn DEC, Boelens PG, Van Norren K, Van Leeuwen 
PAM. Flavonoids: A review of probable mechanisms of action and potential applications. Am 
J Clin Nutr 2001;74:418-425. 
30. Andújar I, Recio MC, Giner RM, Ríos JL. Cocoa polyphenols and their potential benefits 
for human health. Oxidative Medicine and Cellular Longevity 2012;2012:1-23. 
 
 
 
 
  31 
 
 
 
 
 
